QC
VRDN icon

Quadrature Capital’s Viridian Therapeutics VRDN Stock Holding History

Quadrature Capital’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$828K Buy
+45,078
New +$726K 0.01% 795
2026
Q1 		– Sell
-56,781
Closed -$1.77M – 1901
2025
Q4 		$1.77M Buy
+56,781
New +$1.56M 0.02% 385

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Quadrature Capital's VRDN Position: Q2 2026 in Review

Quadrature Capital opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 45,078 shares worth $828K. The stake represents 0.01% of the portfolio and ranks #795 among its holdings. This is a return to the name: Quadrature Capital previously reported a position in VRDN as recently as Q4 2025.

Quadrature Capital first reported a position in VRDN in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.77M in Q4 2025. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Quadrature Capital held 45,078 shares of Viridian Therapeutics worth $828K as of Q2 2026.
  • Viridian Therapeutics was a new Quadrature Capital position in Q2 2026.
  • Viridian Therapeutics made up 0.01% of Quadrature Capital's portfolio in Q2 2026, its #795 holding.
  • Quadrature Capital first reported a position in Viridian Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Quadrature Capital's Viridian Therapeutics position peaked at $1.77M in Q4 2025.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.